SI2555790T1 - Terapevtska uporaba proteina beta2-mikroglobulina - Google Patents

Terapevtska uporaba proteina beta2-mikroglobulina

Info

Publication number
SI2555790T1
SI2555790T1 SI201130922A SI201130922A SI2555790T1 SI 2555790 T1 SI2555790 T1 SI 2555790T1 SI 201130922 A SI201130922 A SI 201130922A SI 201130922 A SI201130922 A SI 201130922A SI 2555790 T1 SI2555790 T1 SI 2555790T1
Authority
SI
Slovenia
Prior art keywords
therapeutic use
microglobulin protein
microglobulin
protein
therapeutic
Prior art date
Application number
SI201130922A
Other languages
English (en)
Inventor
Marcel Mersel
Clovis Rakotoarivelo
Original Assignee
Beta Innov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Innov filed Critical Beta Innov
Publication of SI2555790T1 publication Critical patent/SI2555790T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
SI201130922A 2010-04-08 2011-04-06 Terapevtska uporaba proteina beta2-mikroglobulina SI2555790T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10290188A EP2374470A1 (fr) 2010-04-08 2010-04-08 Utilisation thérapeutique de la protéine Beta2m
US34661710P 2010-05-20 2010-05-20
PCT/IB2011/051476 WO2011125029A1 (en) 2010-04-08 2011-04-06 THERAPEUTIC USE OF THE ß2m PROTEIN
EP11717774.1A EP2555790B1 (en) 2010-04-08 2011-04-06 THERAPEUTIC USE OF THE ß2-MICROGLOBULIN PROTEIN

Publications (1)

Publication Number Publication Date
SI2555790T1 true SI2555790T1 (sl) 2016-09-30

Family

ID=42315462

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130922A SI2555790T1 (sl) 2010-04-08 2011-04-06 Terapevtska uporaba proteina beta2-mikroglobulina

Country Status (20)

Country Link
US (2) US20130017212A1 (sl)
EP (2) EP2374470A1 (sl)
JP (3) JP5955833B2 (sl)
KR (1) KR101889564B1 (sl)
CN (2) CN108159398A (sl)
BR (1) BR112012025537A2 (sl)
CA (1) CA2793940C (sl)
CY (1) CY1117968T1 (sl)
DK (1) DK2555790T3 (sl)
ES (1) ES2588710T3 (sl)
HR (1) HRP20161022T1 (sl)
HU (1) HUE030420T2 (sl)
LT (1) LT2555790T (sl)
PL (1) PL2555790T3 (sl)
PT (1) PT2555790T (sl)
RS (1) RS55121B1 (sl)
RU (1) RU2582389C2 (sl)
SI (1) SI2555790T1 (sl)
SM (1) SMT201600301B (sl)
WO (1) WO2011125029A1 (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374470A1 (fr) * 2010-04-08 2011-10-12 Beta Innov Utilisation thérapeutique de la protéine Beta2m
CN102716379A (zh) * 2012-06-25 2012-10-10 毕建飞 一种治疗强直性脊柱炎的中药组合物
CN116515000A (zh) * 2023-06-30 2023-08-01 迦进生物医药(上海)有限公司 Hfe融合蛋白及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
DE69124372T2 (de) 1990-05-10 1997-08-07 Dana Farber Cancer Inst Inc Erhöhung der assoziation exogener peptide mit mhci-molekülen auf zellen des immunsystems
JPH07118163A (ja) * 1993-10-21 1995-05-09 Mitsui Toatsu Chem Inc β２−ミクログロブリンを含有する組成物
FR2735984B1 (fr) * 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
US6100891A (en) 1998-06-09 2000-08-08 Teledirect International, Inc. Call center agent interface and development tool
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
AU2001296303A1 (en) * 2000-09-22 2002-04-02 Ramot At Tel Aviv University Ltd. A soluble beta 2 microglobulin (beta2m)/hfe monochain for biotechnological and therapeutic applications
GB0115071D0 (en) * 2001-06-20 2001-08-15 Avidex Ltd Substances
US20040265272A1 (en) * 2001-09-28 2004-12-30 Aikichi Iwamoto Mammalian cell-infecting virus vector encoding epitope-bound beta2m and utilization thereof
AU2003221886A1 (en) * 2002-04-12 2003-10-27 The Board Of Trustees Of The University Of Arkansas Beta2-MICROGLOBILIN (Beta2m) AND ANTI-Beta2m BINDING AGENTS AS ANTI-CANCER THERAPEUTICS
US20040127445A1 (en) 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
JP4740531B2 (ja) * 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
AU2004275649A1 (en) 2003-09-30 2005-04-07 Snow Brand Milk Products Co., Ltd. Agent for promoting osteogenesis and/or inhibiting bone resorption
EP2374470A1 (fr) * 2010-04-08 2011-10-12 Beta Innov Utilisation thérapeutique de la protéine Beta2m
CN112303586A (zh) 2019-07-31 2021-02-02 华域视觉科技(上海)有限公司 车辆照明装置、车辆大灯及车辆

Also Published As

Publication number Publication date
JP2018076356A (ja) 2018-05-17
PL2555790T3 (pl) 2016-12-30
CY1117968T1 (el) 2017-05-17
JP2016145208A (ja) 2016-08-12
RS55121B1 (sr) 2016-12-30
US20130017212A1 (en) 2013-01-17
CN102869368A (zh) 2013-01-09
JP2013523808A (ja) 2013-06-17
BR112012025537A2 (pt) 2016-06-21
ES2588710T3 (es) 2016-11-04
WO2011125029A1 (en) 2011-10-13
EP2555790B1 (en) 2016-06-08
KR101889564B1 (ko) 2018-08-17
LT2555790T (lt) 2016-09-12
US20170035846A1 (en) 2017-02-09
HUE030420T2 (en) 2017-05-29
HRP20161022T1 (hr) 2016-10-21
KR20130086133A (ko) 2013-07-31
US11484571B2 (en) 2022-11-01
DK2555790T3 (en) 2016-09-12
CA2793940C (en) 2019-07-09
SMT201600301B (it) 2016-11-10
CA2793940A1 (en) 2011-10-13
RU2582389C2 (ru) 2016-04-27
PT2555790T (pt) 2016-09-09
EP2374470A1 (fr) 2011-10-12
EP2555790A1 (en) 2013-02-13
RU2012147460A (ru) 2014-05-20
JP6703973B2 (ja) 2020-06-03
JP5955833B2 (ja) 2016-07-20
CN108159398A (zh) 2018-06-15

Similar Documents

Publication Publication Date Title
HRP20181615T1 (hr) Terapijsko sredstvo koje izaziva citotoksičnost
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
SG10201507120TA (en) Treatment of diseases
GB201004020D0 (en) New therapeutic use
HK1201454A1 (en) Therapeutic agents and uses thereof
IL223667B (en) 4a100s antibodies and medical uses thereof
EP2605786A4 (en) THERAPEUTIC PEPTIDES
GB201011411D0 (en) Therapeutic compounds and their use
GB201005394D0 (en) Therapy
RS55121B1 (sr) Terapeutska primena proteina ss2-mikroglobulina
HK1182712A1 (en) Therapeutic agents 976 976
GB201016864D0 (en) Therapeutic methods
GB201021708D0 (en) Novel Therapeutic use
GB201019938D0 (en) Determination of therapeutic agents
GB201014963D0 (en) Therapeutic agents
GB201012101D0 (en) Therapeutic agents
GB201012100D0 (en) Therapeutic agents
GB201012102D0 (en) Therapeutic agents
GB201010582D0 (en) Therapeutic agents
GB201010583D0 (en) Therapeutic agents
GB201010577D0 (en) Therapeutic agents
GB201009614D0 (en) Therapeutic use of compounds
IL226635B (en) Human anti-sod1 antibodies
GB0921430D0 (en) Protein for therapeutic use